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Abstract Organ-directed gene transfer remains an attractive
method for both gaining a better understanding of heart
disease and for cardiac therapy. However, virally mediated
transfer of gene products into cardiac cells requires pro-
longed exposure of the myocardium to the viral substrate.
Pericardial injection of viral vectors has been proposed and
used with some success to achieve myocardial transfection
and may be a suitable approach for transfection of atrial
myocardium. Indeed, such an organ-specific method would
be particularly useful to reverse phenotypes in young and
adult genetically altered murine models of cardiac disease.
We therefore sought to develop a minimally invasive tech-
nique for pericardial injection of substances in mice. Peri-
cardial access in anaesthetised, spontaneously breathing
mice was achieved using continuous high-resolution ultra-
sound guidance. We could demonstrate adequate delivery of
injected substances into the murine pericardium. Atrial
epicardial and myocardial cells were transfected in approx-
imately one third of mice injected with enhanced green
fluorescent protein-expressing adenovirus. Cellular expres-
sion rates within individual murine atria were limited to a
maximum of 20 %; therefore, expression efficiency needs to
be further improved. Minimally invasive, ultrasound-guided
injection of viral material appears a technically challenging
yet feasible method for selective transfection of atrial epi-
and myocardium. This pericardial injection method may be
useful in the evaluation of potential genetic interventions
aimed at rescuing atrial phenotypes in transgenic mouse
models.
Keywords Pericardial injection . Transgenic mice . Murine
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Introduction
Organ-specific, transient modification of gene expression is
an attractive method for the pathophysiological understanding
of heart disease and carries hopes for the development of new
treatment methods. In view of the ready availability of genet-
ically altered models, genetically modified mice have become
a predominating model organism for investigating molecular
mechanisms of heart disease. An efficient but minimally in-
vasive cardiac gene transfer technique for murine models
would substantially advance the study of relevant signalling
mechanisms associated with cardiomyopathy and their rever-
sal in mice. Furthermore, it would enable the preclinical
evaluation of cardiac gene therapy.
In order to transfect cardiac tissue in vivo, vectors carry-
ing gene products are predominantly delivered via thoracot-
omy and are either directly injected into the inner cavum of
the left ventricle or intramyocardially (pigs: Mack et al.
1998; rabbits: Safi et al. 1999; dogs: Von Harsdorf et al.
1993). Another technique hitherto mostly limited to larger
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animals but starting to be explored in mice is catheter-based
intracoronary infusion (Xu et al. 2006; Kornowski et al.
2000; Li et al. 2011; Roth et al. 2004a, b).
Intramyocardial administration is limited by the circum-
scribed region of genetic expression surrounding the needle
tract, the result of a lack of diffusion following delivery
(Guzman et al. 1993; Gilgenkrantz et al. 1995; Li et al. 1995;
Niwano et al. 2008). Multiple injections are usually not practi-
cable on account of the relatively invasive nature of the afore-
mentioned methods. Furthermore, multiple intramyocardial
injections are often associated with local tissue damage (French
et al. 1994; Magovern et al. 1996; Guzman et al. 1993).
Pericardial application of genetic vectors appears to be a
promising approach that avoids the limitations associated
with myocardial injections. Thus far, particularly in rodents
but also in larger mammals, pericardial access has been
gained mainly through thoracotomy, e.g. in pigs (thoracot-
omy: Lamping et al. 1997), dogs (thoracotomy, catheter:
Lazarous et al. 1999), rats (thoracotomy: Grkovic et al.
2005; Aoki et al. 1997; Bott-Flügel et al. 2005) and mice
(thoracotomy: Fromes et al. 1999; Roth et al. 2004a, b).
Thoracotomy carries a 10–15 % risk of periprocedural
mortality (Wu et al. 2003), and repeated treatment is
impracticable.
Therefore, a method which avoids surgery and optimises
genetic transfection in regions of the heart not easily acces-
sible by direct injection, such as the atria or the right ven-
tricle, would be preferable. Here, we report on the
development of a method of echo-guided pericardial injection
of viral vectors in mice.
Materials and methods
In order to develop and validate pericardial, ultrasound-
guided delivery of vectors, the following experiments were
performed:
1. Pericardial injections with the diagnostic dye indocya-
nine green to verify in vivo delivery of substances to the
pericardial space and the heart ex vivo.
2. Pericardial injections with recombinant adenovirus
expressing enhanced green fluorescent protein (EGFP).
This method was used in wild-type (WT) mice and in
murine models of atrial pathology to test whether precise
injection is feasible in physiological and pathologically al-
tered hearts.
Animals
During the first episode of the study, experiments were
performed in WT mice on a CD1 and FVB strain back-
ground. Morphological changes in transgenic hearts modify
conditions for cardiac injections; therefore, sex- and age-
matched pairs of WT mice and transgenic mice under con-
trol of the α-MHC promoter were also injected in all epi-
sodes of the protocol. The genotypes were identified by
polymerase chain reaction with the use of genomic tail
DNA as previously reported.
All experiments and animal care procedures were ap-
proved by the local animal care and use committee (64-
M1.18/06).
Echocardiographically guided injections
With a view to performing cardiac gene therapy by injecting
recombinant adenovirus into the pericardial sac of transgen-
ic mice, we developed a method of ultrasound-guided per-
cutaneous injections. This technique was used in all
experiments reported here.
Mice were anaesthetised with 2 % isoflurane (98 % ox-
ygen) and hearts were visualised using a high-resolution
Vevo 770 system and a 20- to 60-MHz real-time micro-
visualisation scanhead probe, respectively, a Vevo 2100
system and a 13- to 24-MHz MicroScan™Transducer (Vi-
sual Sonics, Toronto, Canada). Anaesthesia depth was close-
ly monitored and the isoflurane dose adjusted accordingly.
The chests of the animals were shaved and further cleaned
by a chemical hair remover to minimise ultrasound attenu-
ation and artefacts. Anaesthetised mice were fixed in a
supine position by atraumatic clinical tape. Before position-
ing the ultrasound probe, centrifuged ultrasonic gel free of
trapped air was applied to the exterior thoracic surface. Of
the injection substance, 70 μl was loaded into a 1-ml syringe
fitted with a sterile disposable 30-gauge needle. The needle
was inserted 2 mm beneath the right part of the sternum
through the body wall and directed in a transdiaphragmal
direction towards the heart at ∼30° to the mouse table
surface (Fig. 1). Visualising a modified long axis view
(LAV) in B mode, the needle was gently advanced under
ultrasound guidance until the needle tip was positioned in
the pericardial sac near the right atrium. Correct positioning
of the needle was verified by echocardiographic control and
tactile vibration recognised by the person injecting (Fig. 2).
Of the substance, 70 μl was administered and the needle
removed quickly under echocardiographic control. Vigour
of the heart and heart rate were monitored throughout and
immediately after injection.
In total, 298 injections were performed: 150 hearts were
harvested within 24 h post-injection, whilst the remaining
148 mice were monitored over the following 7 days after the
injection to enable any complications to be identified.
The number of injections performed illustrates the devel-
opment of an effective injection method which involved the
following developmental steps:
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1. Formation and improvement of the experimental setup
including material and procedures
In pretests, alternative mouse positions, e.g. the
lateral position usually used during echocardiograph-
ic assessment, and different echocardiographic views
were tested. The supine position adopted from peri-
cardiocentesis in humans provided the easiest access
and the least complication. After alternative mouse
positioning, four of nine animals showed complica-
tions, e.g. discomfort (4) and post-interventional
death (1), and indocyanine green was found within
the thorax. We therefore decided to pursue the su-
pine position even though alternative positioning
may be feasible, if practised. Lowering heart rate
to about 350 bpm during the procedure facilitated
monitoring of the injection via echocardiography
and positioning the needle and was easily achieved
by sparing heating during anaesthesia.
One hundred fifty-eight injections were performed
using disposable syringes (B. Braun, Injekt®-F,
0.15-0.30 Euro/item), 97 with autoclaved Hamilton
syringes (MicroliterTM, no. 710; ground glass tip,
Luer Tip, needle not included, between 70.00 and
90.00 euro/item) and 43 with insulin syringes (B.
Braun, Omnican 40, 0.10–0.24 euro/item). Light and
cost-effective disposable syringes with an extra nee-
dle showed the highest resistance during injection,
but resistance is unwanted during quick and local-
ised handheld manipulation. Hamilton syringes were
initially more smooth to inject with, but became less
smooth-running after repeated use in our experi-









Fig. 1 Method of pericardial
injection. a Photographic
illustration of transducer
location and syringe during
injection. b Scheme of
experimental setup with
anaesthetised mouse in supine
position in top view and lateral
perspective, needle entry 2 mm
right beneath the edge of the
sternum; transdiaphragmal
direction towards the heart at
























showing the position of the
needle tip inside the pericardial
sac for the pericardial injection
in characteristic RV position
(left) and scheme (right). IVS
interventricular septum, LA left
atrium, LV left ventricle, RA
right atrium, RV right ventricle
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syringes (43) with a fixed needle turned out to be a
good compromise, being easy to handle and reason-
ably priced. The learning curve shows no difference
in success rate between the use of Hamilton syringes and
disposable insulin syringes (Fig. 4).
2. Optimisation of injection substances including pretests
with different volumes and supplements
The diagnostic dye indocyanine green (70 µl,
11 mg/kg) was tolerated by the mice without any changes
in general condition or behaviour. In contrast, injection of
50 µl or 15 mg/kg methylene blue was associated with
death in three of three mice injected within hours after
pericardial injection, possibly caused by a fatal methylene
toxicity in connection with serotonin syndrome (Ng and
Cameron 2010; Gillman 2010; Rowley et al. 2009).
To facilitate penetration of the dye through the pericar-
dial wall, we tested the use of collagenase and hyaluron-
idase, enzymes that degrade the extracellular matrix.
During pretests with collagenase (20 µl, 4 mg/kg) alone
or in combination with hyaluronidase (50 µl, 5805 U/kg),
7 of 11 mice died shortly after pericardial injections,
and the other four were euthanised thereafter to avoid
discomfort. Autopsy revealed in 7 of 11 cases a rupture
of the diaphragm, three times with prolapse of the
liver, and in four cases pulmonary haemorrhage. In
contrast, hyaluronidase alone was well tolerated by
the mice. We therefore concluded that this volume
and concentration of collagenase and hyaluronidase
used in combination was too aggressively digesting adja-
cent tissues.
Finally, we tested different injecting volumes of indoc-
yanine green (9×<50 μl, 76× 50 μl, 96× 60 μl, 80×70 μl,
30×80 μl, 7×100 μl). Mice tolerated injecting volumes
from 50 to 80 μl without any restrictions in general
condition. Behaviour was unchanged and the fur well-
groomed; activity did not decrease. Injection of 100 μl
prolonged the recovery time.
3. Adaptation of experimental setup to genetically modi-
fied mice with altered hearts and injection conditions
After 175 pericardial injections in WT mice, addi-
tional 108 injections in alpha MHC-expressing mice
with enlarged atria were performed. The slight drop in
the success rate after 180 injections (Fig. 4) might
illustrate that adaptation to a different heart anatomy
was necessary until previous results were reproducible.
4. Cardiac injections with recombinant adenovirus
expressing EGFP to assess effectiveness of transfection
After described pretests, we performed cardiac injec-
tions with recombinant adenovirus expressing EGFP un-
derlying former described conditions. Mice were lying in
a supine position and the hearts were visualised by echo-
cardiography in a modified long axis view. Heart rate was
lowered to 350 bpm. Hamilton syringes or disposable
insulin syringes were used. Injecting volume was 70 μl
containing hyaluronidase dissolved in a phosphate buffer
(30 μl) with viral stock solution (40 μl).
Pericardial application of indocyanine green
Indocyanine green (70 μl; Cardio Green, Indocyanine
Green; Sigma-Aldrich Chemie GmbH, Steinheim, Ger-
many) was injected into the pericardium using the injecting
method described above. Within 24 h after injection, the
hearts as well as bordering structures (lung, mediastinum
and diaphragm) were examined for indocyanine green stain-
ing and removed under deep terminal anaesthesia. Tissues
were also studied for scar tissue, necrosis and punctures.
Abdominal organs were inspected.
Pericardial application of recombinant adenovirus
The E1/E3-deleted replication-deficient adenovirus vector
was constructed and propagated in HEK 293 cells according
to standard protocols using the AdEasy system (Xu et al.
2006; He et al. 1998). In this system, a recombinant adeno-
viral plasmid is generated by cloning the gene of interest
into the viral backbone using a minimal number of enzy-
matic manipulations. Transfection of this plasmid into the
HEK 293 cell line facilitates viral propagation, producing a
high titre of viral lysate containing the gene of interest
tagged with EGFP. Visualisation of fluorescence facilitates
monitoring of expression (He et al. 1998).
An adenoviral vector was chosen for this application due
to its previous use as a temporary vector for gene transfer
into the heart (Gilgenkrantz et al. 1995; Magovern et al.
1996) by methods including direct injection or coronary
infusions (Guzman et al. 1993; French et al. 1994; Wasala
2011). The transduction solution injected contained hyal-
uronidase dissolved in a phosphate buffer (30 μl) with viral
stock solution (40 μl). Injected hearts were harvested 4–
10 days post-injection and examined for EGFP expression.
Analysis of atrial EGFP expression
Atrial EGFP-expressing syncytial cells were counted using
direct fluorescence microscopy. Hearts were embedded in
paraffin and heart sections (5 μm in thickness) were cut either
through the separated atria or along the longitudinal axis of the
heart. Atrial expression rates were calculated using the total
number of myocytes on the same section as a denominator.
Electrocardiological experiments
Animals receiving adenovirus underwent electrophysiolog-
ical evaluation before and after injection. In eight freely
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roaming mice, telemetric long-term Holter ECG recordings
(EMKA Technologies, Paris, France) were performed fol-
lowing published methods (Fabritz et al. 2010; Kirchhof et
al. 2006; Bett et al. 1994). Similarly, six-lead electrocardio-
grams (EMKA Technologies) were recorded and analysed
every 24 h in nine mice for 4–10 days (Fabritz et al. 2004).
Heart rate (HR) and arrhythmia were assessed at baseline
directly before and after injection during challenge with
isoproterenol and by hot air jet stress (Froese et al. 2012;
Wittköpper et al. 2010; Kirchhof et al. 2006; Bett et al.
1994).
Echocardiographic evaluation
Mice injected with adenoviral vector underwent echocardio-
graphic evaluation before and 8 days after injection. Cardiac
morphology, size and function following standard protocols
for anaesthetised mice (oxygenated isoflurane 1.5 % by
inhalation, n05 per group, Vevo 770 system) were evaluated
(Kirchhof et al. 2003, 2006, 2011, 2012; Fabritz et al. 2004,
2011). Echocardiography was also used to determine left
atrial size and left atrial function in vivo (Blana et al. 2010).
Statistical analysis
The data are presented as the mean±SEM. Statistical differ-
ences were determined using Student’s t test and Fisher’s




Two hundred ninety-eight cardiac injections were performed
in 190 wild-type mice of different strains and in 108 alpha
MHC-expressing mice with enlarged atria (mean age, 13±
1 weeks). Two hundred of the echo-guided injections were
accomplished using indocyanine green, 39 with the recom-
binant adenovirus (mean age, 8±1 weeks).
In general, mice recovered quickly after injections. How-
ever, 9 of 298 mice died during or immediately after injec-
tion, corresponding to a mortality rate of 3 %, mostly related
to procedural complications: Four mice showed thrombotic
material inside the thorax or abdomen as a sign of thoracic
or abdominal lacerations, including one splenic rupture; one
animal showed intraventricular necrosis, one showed peri-
cardial tamponade, and one developed an air embolisation
after unintended intraventricular injection.
Complications during early optimisation of the experi-
mental setup, e.g. injection of methylene blue or application
of a combination of collagenase and hyaluronidase, were not
included in the peri-interventional survival statistics.
Demonstration of substance delivery into the pericardial
space
Analysis following indocyanine green injection
Upon autopsy, indocyanine green was still found in the
pericardial space in 60 of 239 mice (25 %; Fig. 3). In the
majority of mice, the myocardium was superficially treated
in addition to the pericardial sac. Only in 8 % of mice was
the pericardium treated without any evidence of superficial
treatment of myocardium (19 of 239). At autopsy, indocya-
nine green was observed to stain myocardium in 48 % of
mice (103 of 239). Superficial myocardial marks were ob-
served. Myocardial administration was not deep and indoc-
yanine green was not detected inside the lumen of the
ventricle or atria. In 7 % of mice (17 of 239), staining of
the lungs was detected (Fig. 3).
The diagnostic dye inocyanine green stained mainly the
atria. Where the pericard was stained (in 60 of 239 %
injections), 58 % was documented as atrial, 10 % in the
pericard alongside the RV, 2 % alongside the LV, and in
30 %, indocyanine green was either spread all over the
pericardium or a part not documented in detail. From the
experiments with indocyanine green, we learnt that the atria
were stained more intensively than the ventricles. Therefore,
we concentrated our efforts on the atria regarding GFP
expression.
Injection success rate steadily improved: after 160 inter-
ventions, successful pericardial application/myocardial
staining almost reached 100 %. Interruptions in practise
for extended periods of time or change in substrate (e.g.
different age group or genetically altered mice) may result in
a drop in the success rate (Fig. 4).
Gene transfer efficiency after application of EGFP
adenovirus
After establishing and optimising the technique for pericardial
injection, we went on to assess the feasibility of transducing
myocardial cells by injection of an EGFP-containing adeno-
virus (8–10 μl) into the pericardium. The fraction of EGFP-
expressing cells in the atria varied from 8 to 20 % (Fig. 5).
At 6 weeks of age, the success rate of perimyocardial trans-
fection was 37 % (10 of 27 hearts). Our analyses after GFP
injection following the described injection method revealed
GFP transduction of the right and left atrium in equal measure.
In the 13 hearts of the investigated subgroup, transduction was
found seven times in the LA and seven times in the RA.
To study expression differences within the atrial tissue,
we counted the occurrence of transfections in a subgroup of
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samples at different localisations within the atrial tissues and
compared the results using Fisher’s exact test. The major
group of fluorescent cells was located pericardially or epi-
cardially rather than endocardially (p<0.05), with the
atrial myocardium expressing an intermediate number of
fluorescent cells (Fig. 5).
Pericardial injection does not alter cardiac function
Under freely roaming conditions (Fig. 6a, b), resting heart
rate and maximal heart rate did not differ before and after
pericardial injections (resting HR: n07, 3 WT, 4 transgenic






































Fig. 3 Detection of indocyanine green in myocardium (a, b) and
pericardial sac (a–c) after echocardiography-guided injections. c The
heart still inside the thorax in long axis view. Right, Circle diagram











Fig. 4 Learning curve for echocardiography-guided injections. Pitfalls
and critical steps are labelled above and changes in injection conditions
described beneath learning curve bars. Interruption of injections for
nearly 3 months after injection; number 192 resulted in a drop in
success rate
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±14 bpm; maximal HR: WT0592±34 vs. 582±23 bpm;
TG0701±75 vs. 549±22 bpm).
During air jet stress tests, maximal HR was comparable
before and after injection (n07, 781±14 vs. 816±48 bpm),
whilst the mean HR was lower after injection (n07, 664±15
vs. 572±28 bpm, p<0.05). Cardiac function as assessed by
serial transthoracic echocardiography before and after injection
did not differ (Table 1).
Nevertheless, we monitored HR in the same cohort dur-
ing daily six-lead electrocardiograms in sedation. HR was
significantly increased in these mice if the pre- and post-
injection hearts rate were compared for WT and TG mice
together as one group from day 3 following pericardial
injections of GFP virus solution to day 9 (n09: n04 WT,
n05 TG, 399±16 bpm pre-injection vs. 447±24 bpm at
3 days, 450±22 bpm at 4 days, 446±21 bpm at 5 days,
472±26 bpm at 6 days, 466±17 bpm at 7 days, 463±
19 bpm at 8 days, 445±27 bpm at 9 days, p<0.05).
Considering these results, the presence of some pericardial
effusion induced by the pericardial injection is suggested,
but we did not detect signs of pericardial effusion when
performing echocardiographic assessments at day 8 after
injection (Fig. 7).
Overall, there was no conclusive evidence of alteration of
cardiac function.
Discussion
Here, we report an ultrasound-guided technique for mini-
mally invasive atrial-targeted substance and gene delivery in
mice. Mice regained consciousness only minutes after min-
imally invasive injections, and procedures lasted only a few
minutes. Rare mortality (3 %) was due to misplacement of
the needle outside of the pericardial space, indicative of the
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Fig. 5 Atrial EGFP expression after pericardial injection: Transduction
ofmidmyocardial cells (a, b), transfection of different cell layers (c–f) and
visceral pericardial cells (g, h). Higher magnification (h) reveals that
myocardial cells are not affected in this example. Nuclei were stained
with DAPI DNA stain, appearing blue. i Distribution of GFP transfection
in different cardial cell layers throughout the atria. Endocardial cells are
significantly less transduced than epicardial or pericardial, with the trial
midmyocardium showing intermediate expression
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Fig. 6 Telemetric investigation
before and after pericardial
injection. a Telemetric
equipment. b Telemetric ECG
recording from a freely moving
WT mouse and a TG mouse
during normal activity before
(left) and after (right) echo-
guided injection
Table 1 Cardiac dimensions in
WT and TG mice as measured
by high-resolution echocardiog-
raphy before and 8 days after
echo-guided cardiac injection
HR heart rate, LA left atrial, d
diastolic, s systolic, FS fractional
shortening, MV mitral valve
Doppler, IVS intraventricular
septum, PWEDd posterior wall
end diastolic diameter, LVEDs
left ventricular end systolic di-
ameter, EF ejection fraction, CO
cardiac output
Parameters Pre-injection 8 days post-injection p values
WT TG WT TG Pre vs. post
WT TG
Atria Body weight (g) 27.1±2.5 30.5±1.5 27.1±2.5 30.2±1.8 0.996 0.919
HR (bpm) 391±20 379±37 458±22 417±41 0.061 0.518
LAs (mm) 1.26±0.18 1.54±0.26 1.26±0.24 1.96±0.20 0.996 0.249
LA FS (%) 27±5 25±4 26±2 22±2 0.755 0.557
MV E (cm/s) 87.1±13.6 71.0±11.9 91.4±12.2 73.9±1.8 0.821 0.824
MVA (cm/s) 45.6±5.2 46.3±9.5 55.0±1.5 50.7±0.5 0.165 0.674
IVSd (mm) 0.87±0.03 0.80±0.03 0.80±0.02 0.77±0.01 0.121 0.446
Ventricle PWEDd (mm) 0.81±0.02 0.81±0.03 0.81±0.02 0.91±0.06 0.884 0.216
LVEDd (mm) 3.96±0.22 4.00±0.11 3,92±0.99 3.93±0.12 0.850 0.673
LVEDs (mm) 2.5±0.09 2.70±0.24 2.43±0.19 2.74±0.14 0.541 0.755
FS (%) 32±2 30±2 35±1 31±5 0.284 0.846
EF (%) 61±2 58±3 65±2 59±8 0.271 0.929
CO (ml/min) 24±2 14±4 17±2 12±1 0.069 0.673
LV Mass (mg) 124.4±10.0 117.9±2.2 115.4±7.6 121.4±2.5 0.484 0.331
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Indocyanine green, the dye used during the introductory
phase of the study, proved a reliable dye to track pericardial
delivery. Mice tolerated the diagnostic dye without any
changes in general condition or behaviour, and the dye
was found in the pericardial space after euthanasia up to
24 h after injection. The dye was detected inside the myo-
cardium as well as the pericardial cavity; however, it was
also detected within the lung and mediastinal tissue in rare
cases of needle misplacement.
The myocardium or pericardium was treated in 68 % of
echo-guided injections with indocyanine green, which docu-
ments a satisfying success rate. In addition to being a short,
well-tolerated procedure, careful post-procedural electrocar-
diographic and echocardiographic monitoring did not identify
physiologically relevant changes in vital parameters or cardiac
function. Furthermore, transduction of pericardial and
myocardial tissue EGFP-expressing adenoviruses was
achieved in 37 % of mice aged 6 weeks and in 27 % of all
mice studied.
In this study, ultrasound-guided percutaneous injections into
the pericardial cavity of juvenile and adult mouse hearts are
described for the first time. This type of application immerses
the heart in the applied substance and thereby exposes it to the
vector for a prolonged time, thereby making parts of the heart
that are difficult to access directly, e.g. the left atrium, accessible.
To date, direct injection into the myocardium or catheter-
based intracoronary infusion in mice has not been easily
achievable, and the resulting transgene expression is limited
to the local region around the needle tract or the myocardium
supplied by the selective coronary artery (Guzman et al. 1993;
Kass-Eisler et al. 1993; Barr et al. 1994; Logeart et al. 2001).
Unfortunately, direct injection into the myocardium
results in severe local tissue damage, which makes it an
inadequate therapeutic approach (Guzman et al. 1993;
Magovern et al. 1996). Myocardial injections are associated
with significant injury, fibrosis and necrosis at the injection
site, resulting in the accumulation of macrophages and
neutrophils (Aoki et al. 1997).
By following the noninvasive method of ultrasound-
guided pericardial injections as described here, the mouse
heart maintains a prolonged contact time with the vector.
Due to the observed epicardial–endocardial transfection
gradient, the technique allows selective atrial transfection
of epicardial and myocardial tissues (Springer et al.
2005).
Effective pericardial injections have been described in
other species such as dogs (Lamping et al. 1997), rats (Aoki
et al. 1997) as well as in mice (Fromes et al. 1999), but have
always been combined with the invasive procedure of tho-
racotomy. Our strategy offers the potential for repeated
interventions because of the well-tolerated, minimally inva-
sive injection technique, thus enabling experimental designs
with clinically relevant operating schedules, e.g. days or
weeks, after a surgical procedure or regularly for the applica-
tion of locally acting medication.
Zhang et al. (1999) were able to transfect the RVand atria
by percutaneous subxiphoid injection into the pericardial
cavity of 4- to 5-day-old mice, but long-term survival was
compromised in this study: only mice with patchy staining
of superficial cell layers survived more than 2 weeks. The
survival rate increased after reducing the injection volumes,
but this also reduced the level of gene expression. In neo-
natal mice, the pericardium is extensively attached to the
sternum (Nakatani et al. 1988) and, therefore, easier to reach
by injection than in adult animals. Furthermore in neonates,
pericardial pores are absent (Nakatani et al. 1988), further
prolonging exposure to the viral suspension.
Our study demonstrates that atrial-targeted gene transfer by




Fig. 7 Echocardiographic parasternal long axis view two-dimensional
(a) and motion (M) mode (b) of a WT mouse 8 days after pericardial
injection. No evidence for pericardial effusion
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the advantages of neonatal anatomy for this procedure. In
adult mice, validation of correct needle position by ultrasound
is suggested; selecting an RV injecting position near to the
right atrium has led to a satisfactory success rate in this study.
Pericardial injection leads to both left and right atrial EGFP
expression in this study. Gene expression was not limited to
the area around the needle tract, unlike in myocardial injec-
tions, but the atria, exposed to the viral suspension, were also
affected. Atrial EGFP expression was mainly observed in
pericardial cells, but also extended into the myocardium.
Limitations
As with other methods of administration, the expression
levels were still limited in this study. To achieve higher
expression in atrial myocardial cells, further investigations
such as increasing the dose of recombinant adenovirus or
employing a different strategy to permeate the pericardial
barrier are required. The combined use of hyaluronidase and
collagenase was described (Fromes et al. 1999), but not well
tolerated by the mice in our experimental setup.
Outlook
The development of genetic vectors that are not only heart-
specific but also able to target cardiac subregions may be
more effective for atrium-specific gene transfer. To date,
atrium-specific gene transfer has been reported in porcine
hearts by direct application of adenoviral vectors to the
epicardial surface (Kikuchi et al. 2005).
Adeno-associated viral vectors (AAV) with organ-
targeted restricted transgene expression are promising
(Fromes et al. 1999; Müller et al. 2007; Zincarelli et al.
2010). A combination of noninvasive pericardial injection
and tissue-specific vectors could potentially make the de-
scribed strategy more effective (Bish et al. 2011). Another
approach for optimisation may be ultrasound-targeted de-
struction of microbubbles (Ghanem et al. 2009; Walton et al.
2011; Fujii et al. 2011) loaded with AAV (Bish et al. 2011).
Very recently, pericardial application of AAV virus to neo-
natal murine pericardium resulted in cardiac vector expression
and phenotype rescue (Denegri et al. 2012), demonstrating
potential impact on cardiovascular research and therapy.
The closed-chest minimally invasive pericardial injec-
tion technique described in this study may be helpful in
evaluating the therapeutic potential of cardiac genetic
modifications in murine models, especially when targeting
the atria.
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